Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.35 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814384 | 0.70 | CYP2A6 (0.48) | ALDH1A1ALDH1A3ALDH3A1KDM4E | |
| SCHEMBL31299760 | 0.70 | CYP2A6 (0.48) | ALDH1A1ALDH1A3ALDH3A1KDM4E | |
| SCHEMBL2562764 | 0.70 | ALDH1A1 (0.40) | ALDH1A1ALDH1A3ALDH3A1KDM4E | |
| SCHEMBL8568419 | 0.69 | KMT2A (0.41) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5693207 | 0.68 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL2555933 | 0.68 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AALDH1A3ALDH3A1 | |
| SCHEMBL944572 | 0.68 | FDPS (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29953969 | 0.67 | ALDH1A3 (0.43) | ALDH1A1ALDH1A3ALDH3A1KDM4E | |
| SCHEMBL9362085 | 0.66 | ALDH1A3 (0.67) | ALDH1A1ALDH1A3ALDH3A1 | |
| SCHEMBL19594987 | 0.66 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AALDH1A3ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885MEN1 4390/4885KMT2A 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.